GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Shiller PE Ratio

Heidelberg Pharma AG (XTER:HPHA) Shiller PE Ratio : (As of Jun. 19, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Heidelberg Pharma AG Shiller PE Ratio Historical Data

The historical data trend for Heidelberg Pharma AG's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Shiller PE Ratio Chart

Heidelberg Pharma AG Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Heidelberg Pharma AG Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Heidelberg Pharma AG's Shiller PE Ratio

For the Biotechnology subindustry, Heidelberg Pharma AG's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heidelberg Pharma AG's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's Shiller PE Ratio falls into.



Heidelberg Pharma AG Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Heidelberg Pharma AG's E10 for the quarter that ended in Feb. 2024 is calculated as:

For example, Heidelberg Pharma AG's adjusted earnings per share data for the three months ended in Feb. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=-0.1/124.5109*124.5109
=-0.100

Current CPI (Feb. 2024) = 124.5109.

Heidelberg Pharma AG Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201405 -0.180 99.263 -0.226
201408 0.209 99.823 0.261
201411 -0.153 99.543 -0.191
201502 -0.134 99.217 -0.168
201505 -0.086 100.417 -0.107
201508 -0.172 100.617 -0.213
201511 -0.326 99.717 -0.407
201602 -0.096 99.317 -0.120
201605 -0.106 100.617 -0.131
201608 -0.125 101.017 -0.154
201611 -0.173 100.517 -0.214
201702 -0.150 101.217 -0.185
201705 -0.163 101.817 -0.199
201708 -0.230 102.617 -0.279
201711 -0.210 102.117 -0.256
201802 -0.090 102.317 -0.110
201805 -0.082 103.917 -0.098
201808 -0.096 104.517 -0.114
201811 -0.151 104.217 -0.180
201902 -0.110 103.817 -0.132
201905 -0.044 105.418 -0.052
201908 -0.050 106.018 -0.059
201911 -0.160 105.318 -0.189
202002 -0.160 105.618 -0.189
202005 -0.170 106.018 -0.200
202008 -0.098 106.018 -0.115
202011 -0.190 105.018 -0.225
202102 -0.200 107.018 -0.233
202105 -0.220 108.170 -0.253
202108 -0.170 109.118 -0.194
202111 -0.213 110.173 -0.241
202202 -0.210 111.754 -0.234
202205 -0.040 115.760 -0.043
202208 -0.135 116.709 -0.144
202211 -0.140 119.872 -0.145
202302 -0.140 121.454 -0.144
202305 -0.200 122.824 -0.203
202308 0.000 123.878 0.000
202311 -0.100 123.668 -0.101
202402 -0.100 124.511 -0.100

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Heidelberg Pharma AG  (XTER:HPHA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Heidelberg Pharma AG Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Heidelberg Pharma AG (XTER:HPHA) Business Description

Traded in Other Exchanges
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG (XTER:HPHA) Headlines

No Headlines